Clinical Trial Update: Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 1/2 study of the combination of avelumab and M6620 for DDR-deficient metastatic or unresectable solid tumors; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Unresectable Cancer

Drugs mentioned

• Avelumab (avelumab)
• M6620 (berzosertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-20